{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:15Z","timestamp":1790239395795,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":2825,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"PharmaMar S.A., Sociedad Unipersonal","award":["ClinicalTrials.gov number, NCT00579501"],"award-info":[{"award-number":["ClinicalTrials.gov number, NCT00579501"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1093\/annonc\/mdr265","type":"journal-article","created":{"date-parts":[[2011,6,4]],"date-time":"2011-06-04T00:30:58Z","timestamp":1307147458000},"page":"771-776","source":"Crossref","is-referenced-by-count":118,"title":["Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma"],"prefix":"10.1016","volume":"23","author":[{"given":"A.","family":"Gronchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Demetri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Tercero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr265_bb0010","first-page":"267","article-title":"Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia","volume":"18","author":"Orvieto","year":"2001","journal-title":"Semin Diagn Pathol"},{"key":"10.1093\/annonc\/mdr265_bb0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1634\/theoncologist.2007-0165","article-title":"Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose?","volume":"13","author":"Hohenberger","year":"2008","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdr265_bb0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.sla.0000141710.74073.0d","article-title":"The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma","volume":"240","author":"Eilber","year":"2004","journal-title":"Ann Surg"},{"key":"10.1093\/annonc\/mdr265_bb0025","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/1097-0142(19940815)74:4<1265::AID-CNCR2820740414>3.0.CO;2-X","article-title":"Myxoid liposarcoma. Experience with chemotherapy","volume":"74","author":"Patel","year":"1994","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr265_bb0030","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0035","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.9511","article-title":"Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas","author":"Grosso","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdr265_bb0045","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-10-0317","article-title":"Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacological features of human tumors","volume":"16","author":"Frapolli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdr265_bb0050","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","article-title":"A review of trabectedin (ET-743): a unique mechanism of action","volume":"9","author":"D'Incalci","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdr265_bb0055","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","author":"Germano","year":"2010","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdr265_bb0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","article-title":"Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors","volume":"8","author":"Forni","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdr265_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.10000","article-title":"Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript","author":"Grosso","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-009-9262-4","article-title":"Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients","volume":"28","author":"Hollebecque","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdr265_bb0075","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","article-title":"Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study","volume":"23","author":"Garcia-Carbonero","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CCO.0b013e32833aaac1","article-title":"Trabectedin therapy for sarcomas","volume":"22","author":"Casali","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0090","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","article-title":"Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0095","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1517\/14656560903277236","article-title":"Trabectedin: an anticancer drug from the sea","volume":"10","author":"Ganjoo","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdr265_bb0100","first-page":"19","article-title":"Trabectedin (YondelisR; ET-743): a drug of marine origin for soft-tissue sarcoma","volume":"37","author":"Schoffski","year":"2008","journal-title":"Hosp Pharm Eur"},{"key":"10.1093\/annonc\/mdr265_bb0105","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14656566.9.9.1609","article-title":"Clinical impact of trabectedin (ecteinascidin-743) in advanced\/metastatic soft tissue sarcoma","volume":"9","author":"Schoffski","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1093\/annonc\/mdr265_bb0110","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.bjc.6603142","article-title":"A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer","volume":"94","author":"Zelek","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdr265_bb0115","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2165\/00003495-200767150-00009","article-title":"Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer","volume":"67","author":"Carter","year":"2007","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdr265_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.e13510","article-title":"Trabectedin phase II clinical trials: pooled analysis of safety in patients with solid tumors","volume":"27","author":"Cioffi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr265_bb0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdp198","article-title":"Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg\/m2 24 h or 1.3 mg\/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer","volume":"20","author":"Del Campo","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419344357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/3\/771\/605328\/mdr265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T05:05:58Z","timestamp":1624424758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419344357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0923753419344357"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr265","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13101956.14423058","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}